Limits...
Alginate as a protease inhibitor in vitro and in a model gut system; selective inhibition of pepsin but not trypsin.

Chater PI, Wilcox MD, Brownlee IA, Pearson JP - Carbohydr Polym (2015)

Bottom Line: Alginates were shown to reduce pepsin activity by up to 53.9% (±9.5SD) in vitro.Limited inhibition of trypsin was shown.Significant inhibition of proteolysis was shown in the gastric phase of digestion, but not the small intestinal phase.

View Article: PubMed Central - PubMed

Affiliation: Institute for Cell and Molecular Biosciences (ICaMB), Medical School, Newcastle University, Catherine Cookson Building, Framlington Place, Newcastle upon Tyne NE2 4HH, United Kingdom. Electronic address: peter.chater@ncl.ac.uk.

No MeSH data available.


Related in: MedlinePlus

Bovine serum albumin digestion in gastric phase of a model gut system with and without SP54. The graph shows total protein recovered from model gut system after TCA (trichloroacetic acid) precipitation to stop enzyme activity and remove undigested polypeptides. 0.5 g BSA was digested alone (control digestion) and in the presence of varying concentrations of SP54. Control digestion is represented as (■) and digestion with SP54 at 125 mg as (♦), 250 mg (▾) and 500 mg (▴). All samples were tested in triplicate, errors are shown as standard deviation. At T[60] by the end of the gastric phase, 125, 250 and 500 mg of pentosan polysulphate significantly inhibited the gastric digestion of protein by 54.1% (P = 0.0001), 78.9% (P = 0.001) and 87.6% (P = 0.0004), respectively (t-test).
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4539341&req=5

fig0020: Bovine serum albumin digestion in gastric phase of a model gut system with and without SP54. The graph shows total protein recovered from model gut system after TCA (trichloroacetic acid) precipitation to stop enzyme activity and remove undigested polypeptides. 0.5 g BSA was digested alone (control digestion) and in the presence of varying concentrations of SP54. Control digestion is represented as (■) and digestion with SP54 at 125 mg as (♦), 250 mg (▾) and 500 mg (▴). All samples were tested in triplicate, errors are shown as standard deviation. At T[60] by the end of the gastric phase, 125, 250 and 500 mg of pentosan polysulphate significantly inhibited the gastric digestion of protein by 54.1% (P = 0.0001), 78.9% (P = 0.001) and 87.6% (P = 0.0004), respectively (t-test).

Mentions: Pentosan polysulphate (SP54) was used as the positive inhibition control. At all tested concentrations of 50, 100 and 200 mg pentosan polysulphate there was significant inhibition of gastric proteolysis at all time points from T[5] onwards (Fig. 4) At T[5], 50, 100 and 200 mg of pentosan polysulphate significantly inhibited the gastric digestion of protein by 62.5% (P = 0.005), 90.1% (P = 0.003) and 90.5% (P = 0.002), respectively. At T[60] by the end of the gastric phase, 50, 100 and 200 mg of pentosan polysulphate significantly inhibited the gastric digestion of protein by 54.1% (P = 0.0001), 78.9% (P = 0.001) and 87.6% (P = 0.0004), respectively.


Alginate as a protease inhibitor in vitro and in a model gut system; selective inhibition of pepsin but not trypsin.

Chater PI, Wilcox MD, Brownlee IA, Pearson JP - Carbohydr Polym (2015)

Bovine serum albumin digestion in gastric phase of a model gut system with and without SP54. The graph shows total protein recovered from model gut system after TCA (trichloroacetic acid) precipitation to stop enzyme activity and remove undigested polypeptides. 0.5 g BSA was digested alone (control digestion) and in the presence of varying concentrations of SP54. Control digestion is represented as (■) and digestion with SP54 at 125 mg as (♦), 250 mg (▾) and 500 mg (▴). All samples were tested in triplicate, errors are shown as standard deviation. At T[60] by the end of the gastric phase, 125, 250 and 500 mg of pentosan polysulphate significantly inhibited the gastric digestion of protein by 54.1% (P = 0.0001), 78.9% (P = 0.001) and 87.6% (P = 0.0004), respectively (t-test).
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4539341&req=5

fig0020: Bovine serum albumin digestion in gastric phase of a model gut system with and without SP54. The graph shows total protein recovered from model gut system after TCA (trichloroacetic acid) precipitation to stop enzyme activity and remove undigested polypeptides. 0.5 g BSA was digested alone (control digestion) and in the presence of varying concentrations of SP54. Control digestion is represented as (■) and digestion with SP54 at 125 mg as (♦), 250 mg (▾) and 500 mg (▴). All samples were tested in triplicate, errors are shown as standard deviation. At T[60] by the end of the gastric phase, 125, 250 and 500 mg of pentosan polysulphate significantly inhibited the gastric digestion of protein by 54.1% (P = 0.0001), 78.9% (P = 0.001) and 87.6% (P = 0.0004), respectively (t-test).
Mentions: Pentosan polysulphate (SP54) was used as the positive inhibition control. At all tested concentrations of 50, 100 and 200 mg pentosan polysulphate there was significant inhibition of gastric proteolysis at all time points from T[5] onwards (Fig. 4) At T[5], 50, 100 and 200 mg of pentosan polysulphate significantly inhibited the gastric digestion of protein by 62.5% (P = 0.005), 90.1% (P = 0.003) and 90.5% (P = 0.002), respectively. At T[60] by the end of the gastric phase, 50, 100 and 200 mg of pentosan polysulphate significantly inhibited the gastric digestion of protein by 54.1% (P = 0.0001), 78.9% (P = 0.001) and 87.6% (P = 0.0004), respectively.

Bottom Line: Alginates were shown to reduce pepsin activity by up to 53.9% (±9.5SD) in vitro.Limited inhibition of trypsin was shown.Significant inhibition of proteolysis was shown in the gastric phase of digestion, but not the small intestinal phase.

View Article: PubMed Central - PubMed

Affiliation: Institute for Cell and Molecular Biosciences (ICaMB), Medical School, Newcastle University, Catherine Cookson Building, Framlington Place, Newcastle upon Tyne NE2 4HH, United Kingdom. Electronic address: peter.chater@ncl.ac.uk.

No MeSH data available.


Related in: MedlinePlus